CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.719
EU - Europa 3.778
AS - Asia 3.535
SA - Sud America 634
AF - Africa 76
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 3
Totale 20.777
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.626
GB - Regno Unito 1.736
SG - Singapore 1.157
CN - Cina 839
HK - Hong Kong 582
BR - Brasile 534
SE - Svezia 433
IT - Italia 380
DE - Germania 341
VN - Vietnam 334
RU - Federazione Russa 206
TR - Turchia 173
ID - Indonesia 153
FI - Finlandia 130
FR - Francia 130
BG - Bulgaria 105
IE - Irlanda 77
IN - India 64
CA - Canada 48
JP - Giappone 47
AR - Argentina 42
NL - Olanda 38
AT - Austria 30
BE - Belgio 29
KR - Corea 22
ZA - Sudafrica 21
BD - Bangladesh 20
CH - Svizzera 20
IQ - Iraq 20
NZ - Nuova Zelanda 19
UA - Ucraina 19
TH - Thailandia 17
EC - Ecuador 16
ES - Italia 15
RO - Romania 14
SA - Arabia Saudita 14
MX - Messico 13
PK - Pakistan 13
AU - Australia 12
EG - Egitto 12
CO - Colombia 10
MA - Marocco 10
BZ - Belize 9
LT - Lituania 9
PL - Polonia 9
CZ - Repubblica Ceca 8
IR - Iran 8
NO - Norvegia 8
PE - Perù 8
CL - Cile 7
JO - Giordania 7
MY - Malesia 7
PH - Filippine 7
VE - Venezuela 7
KE - Kenya 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
TW - Taiwan 6
UZ - Uzbekistan 6
DK - Danimarca 5
DZ - Algeria 5
IL - Israele 5
JM - Giamaica 5
AZ - Azerbaigian 4
BY - Bielorussia 4
CR - Costa Rica 4
GT - Guatemala 4
LU - Lussemburgo 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
AL - Albania 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LK - Sri Lanka 3
OM - Oman 3
RS - Serbia 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MT - Malta 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AD - Andorra 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
Totale 20.755
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Santa Clara 1.307
Southend 1.304
Ashburn 1.241
Woodbridge 907
Seattle 873
Singapore 833
Houston 779
Cambridge 732
Chandler 692
Wilmington 682
Hong Kong 575
Dearborn 324
Nyköping 307
Ann Arbor 300
London 298
Beijing 162
San Diego 158
Izmir 156
Dong Ket 155
Jakarta 145
Helsinki 111
Sofia 105
New York 104
Princeton 103
Eugene 93
Los Angeles 88
Phoenix 87
Hefei 79
Dublin 75
Shanghai 68
Council Bluffs 64
Ho Chi Minh City 63
Modena 63
Chicago 58
São Paulo 54
Munich 53
The Dalles 50
Bremen 47
Hanoi 44
Buffalo 41
Tokyo 40
Redondo Beach 36
Dallas 31
Milan 29
Redwood City 28
Boardman 26
Lauterbourg 21
Brussels 20
Norwalk 20
Atlanta 19
Auckland 19
Frankfurt am Main 19
Nuremberg 18
San Mateo 18
Bologna 17
Moscow 17
Rio de Janeiro 17
Salt Lake City 17
Zhengzhou 17
Kunming 16
Seoul 16
Turku 16
Guangzhou 15
Montreal 15
Paris 15
Vienna 15
Amsterdam 14
Belo Horizonte 14
Brasília 14
Falkenstein 14
San Jose 14
Mumbai 13
Portsmouth 13
Toronto 13
San Francisco 12
Stockholm 12
Curitiba 11
Düsseldorf 11
Falls Church 11
Johannesburg 11
Nanjing 11
Orem 11
Hounslow 10
Kilburn 10
Ottawa 10
Rome 10
Zurich 10
Belize City 9
Columbus 9
Grafing 9
Jacksonville 9
Lancaster 9
Monmouth Junction 9
Quito 9
Baghdad 8
Brooklyn 8
Changsha 8
Chiswick 8
Hangzhou 8
Totale 16.481
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 580
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 470
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 331
Immunotherapy for colorectal cancer: where are we heading? 288
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 280
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 258
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 252
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 249
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 248
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 243
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 243
Metabolic disorders across hepatocellular carcinoma in Italy 240
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 238
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 238
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 236
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 235
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 233
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 232
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 231
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 231
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 230
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 228
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 227
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 226
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 226
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 225
Immunotherapeutic approaches for hepatocellular carcinoma 225
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 224
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 223
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 222
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 221
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 220
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 220
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 219
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 219
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 218
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 218
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 217
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 214
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 214
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 213
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 211
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 208
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 208
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 207
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 206
Sarcopenia in gastric cancer: when the loss costs too much 206
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 206
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 206
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 205
The Italian Rare Pancreatic Exocrine Cancer Initiative 205
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 204
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 196
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 196
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 194
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 193
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 192
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 190
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 187
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 185
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 185
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 184
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 182
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 181
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 180
Improved stool DNA integrity method for early colorectal cancer diagnosis 180
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 180
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 180
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 179
Clustered protocadherins methylation alterations in cancer 176
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 176
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 176
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 176
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 176
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 173
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 170
Increase of reports of suspected adverse drug reactions in oncology 169
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 163
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 162
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 158
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 158
BRAF-mutated colorectal cancer: Clinical and molecular insights 158
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 157
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 156
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 156
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 155
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 153
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 150
Hemangioblastoma of the gastrointestinal tract: A first case 147
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 144
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 144
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 138
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 131
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 129
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 118
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 118
Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma 116
The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis 109
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis 109
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 108
Totale 20.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.794
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.398 0 0 0 0 0 415 177 384 274 396 383 369
2021/20222.268 318 153 159 113 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20254.052 133 39 33 256 957 686 433 227 449 167 212 460
2025/20262.537 383 232 384 533 913 92 0 0 0 0 0 0
Totale 21.097